Copy

Newsletter 10 - Nov 2015







EURECA in Preparation

Members of the EURECA team from Hospital Universitario Virgen Macarena, Servicio Andaluz de Salud, in Seville, and members of the team at the University of Medical Center of Utrecht met in Utrecht to discuss different aspects related to the management and monitoring plans of the EURECA study. EURECA is an ambitious observational study with the objectives of collecting high quality data from a multinational prospective cohort of patients with infections due to carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Read more..









Study Update REJUVENATE

COMBACTE-CARE’s REJUVENATE will deliver a prospective, open-label, multicenter study to determine the PK and safety & tolerability of aztreonam-avibactam (ATM-AVI) against clinically isolated multi-resistant Gram-negative bacteria in hospitalized adults with an intra-operative or postoperative diagnosis of cIAI. Read more..








IMI - Fiction VS Fact

The Innovative Medicines Initiative (IMI) is a partnership between the European Union and the European pharmaceutical industry that is working to improve the drug development process and so accelerate the development of better, safer medicines for patients. In 2015, certain organisations and outlets have published articles and reports on IMI which include a number of misconceptions and inaccuracies. Read more..








COMBACTE NMS

CLIN-Net is creating a European network of hospitals that are capable and experienced in performing high-quality clinical studies. One of the challenges the CLIN-Net team encounterd is keeping an accurate, up-to-date and clear overview of all the organizations and that are part of this growing Network. The Network Management System (NMS) was developed to handle the large amount of information we are gathering. Read more..
 




 





Aspire-ICU Update

ASPIRE-ICU is a prospective observational study which aims to describe the epidemiology of bacterial infections, especially S. aureus and P. aeruginosa infections, among patients in the ICU. Approximately 30 sites in 10-12 European countries will be selected for the ASPIRE-ICU study. The study team has been working diligently in selecting sites. Read more..
 
 




 

More news


 


Please contact the PMO team with your ideas for the next newsletter.
Click here to send us your thoughts! Looking forward to hearing from you!





Unsubscribe from this newsletter.

This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115523 | 115620 | 115737 resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution.

Email Marketing Powered by Mailchimp